Shares of Ligand Pharmaceuticals plunged 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late-stage study.
CNBC contributor Mike Khouw discusses why he sees Celgene as a "very attractive trade."
The "Fast Money" traders debated whether it's time to pile into the biotech sector after the sector gained 3 percent on Monday.
The "Fast Money" traders give you 5 trades in biotech.
Stocks that would do well in the event of a GOP presidential victory are no longer lagging the Clinton stocks as much as they had been.
With biotechs in the political crosshairs, is now the time to look at the space? With Michael Yee, RBC Capital biotech analyst.
CNBC's Meg Tirrell reports on other price hikes from Mylan apart from its controversial raise of its EpiPen. The "Fast Money" traders weigh in on the drug pricing debate.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.
Pfizer buys Medivation for $14 billion in cash. CNBC's Meg Tirrell reports the latest.
Pfizer is in advanced talks to acquire Medivation for close to $14 billion, as it seeks to boost its oncology portfolio.
Medivation briefly popped Wednesday after reports that at least five pharmaceutical companies expressed interest in buying it.
CNBC's Meg Tirrell reports the latest details on Valeant and its potential criminal probe. The "Fast Money Halftime Report" traders and Yana Barton, Eaton Vance portfolio manager, add perspective.
Biotech stocks this week hit their highest levels since January. And some analysts say the stocks have room to run.
The "Halftime Report" experts discuss BTIG's Celgene upgrade
Biotech stocks have seen a big bounce in the past few weeks, as the group hits its highest level since January. Talking biotech, with David Seaburg, Cowen, and Chad Morganlander, Stifel Nicolaus.
The “Fast Money Halftime Report” traders share their views on Scotts Miracle-Gro and Celgene. Dane Leone, BTIG analyst, weighs in on Celgene.
Biotech hits a 6-month high. The "Fast Money Halftime Report" traders discusses whether they think it's time to buy biotech.
The "Fast Money" traders discuss their views on Biogen.
Jim Cramer reviewed the recent bullish actions taken by Tesla and Uber, and says it could mean big things for historically difficult August.
Michael Yee, RBC analyst, shares his views on the biotech breakout. The "Fast Money" traders weigh in.